Two global registries run by clinicians and researchers at Guy’s and St Thomas’ have launched to understand the impact of COVID-19 on people with psoriasis.
The PsoProtect registry collects data from clinicians around the world on patients with psoriasis and COVID-19, while the PsoProtectMe registry collects data from patients themselves (whether or not they have suffered from COVID-19) on their experiences and behaviours in the pandemic.
The registries are international collaborations between clinicians, scientists, epidemiologists and patient representatives that seek to better understand the underlying determinants of the outcome of COVID-19 in patients with the inflammatory skin condition psoriasis.
Psoriasis is a common skin disease affecting 2-4% of people worldwide. It is caused by an overactive immune system, and affected individuals develop red, scaly patches of skin that can be itchy and painful.
At present, it is not understood how COVID-19 affects people with psoriasis, and whether there is a need for clinicians and patients to be considering adapting their usual immunosuppressant treatments. The researchers hope the registries will collect data to help answer these questions.
Dr Satveer Mahil and Professor Catherine Smith at the St John’s Institute of Dermatology at Guy’s and St Thomas’ are co-directors of the registries.
Dr Satveer Mahil said: “By collecting observational data from clinicians on a global scale, PsoProtect has the potential to rapidly improve our understanding of how factors such as systemic immunosuppressant therapies, underlying medical conditions and demographic variables including age, sex and ethnicity affect outcomes of COVID-19 in psoriasis.
“Patient-reported outcomes of COVID-19, and understanding the experiences and health behaviours of all individuals with psoriasis during the pandemic are also key considerations for informing clinical care. We are very excited to be collecting this information directly from patients in PsoProtectMe.
“We are incredibly grateful to all of the patients and clinicians who are contributing to the registries and helping us to gather a wide range of data. We hope that this information will help inform assessments of risk of COVID-19 in individuals with psoriasis and guide clinical decision making around their treatments in the pandemic.”